These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33513604)

  • 1. LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome.
    Thurner L; Fadle N; Bittenbring JT; Regitz E; Schuck R; Cetin O; Stuhr A; Rixecker T; Murawski N; Poeschel V; Kaddu-Mulindwa D; Preuss KD; Stilgenbauer S; Hermine O; Kluin-Nelemans HC; Hartmann S; Dreyling M; Pott C; Bewarder M; Hoster E
    Blood; 2021 Jun; 137(23):3251-3258. PubMed ID: 33513604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.
    Thurner L; Hartmann S; Fadle N; Kemele M; Bock T; Bewarder M; Regitz E; Neumann F; Nimmesgern A; von Müller L; Pott C; Kim YJ; Bohle RM; Wasik M; Schuster SJ; Hansmann ML; Preuss KD; Pfreundschuh M
    Leukemia; 2019 Jan; 33(1):148-158. PubMed ID: 29955130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
    Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
    J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
    Dreyling M; Lenz G; Hoster E; Van Hoof A; Gisselbrecht C; Schmits R; Metzner B; Truemper L; Reiser M; Steinhauer H; Boiron JM; Boogaerts MA; Aldaoud A; Silingardi V; Kluin-Nelemans HC; Hasford J; Parwaresch R; Unterhalt M; Hiddemann W
    Blood; 2005 Apr; 105(7):2677-84. PubMed ID: 15591112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
    Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
    Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical analysis of 140 cases of mantle cell lymphoma].
    Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
    Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
    Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
    Klener P; Fronkova E; Kalinova M; Belada D; Forsterova K; Pytlik R; Blahovcova P; Simkovic M; Salek D; Mocikova H; Prochazka V; Janikova A; Vaskova M; Mejstrikova E; Kodet R; Trka J; Trneny M
    Hematol Oncol; 2018 Dec; 36(5):773-778. PubMed ID: 30129045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report.
    Jo JC; Kim SJ; Lee HS; Eom HS; Lee SI; Park Y; Lee JO; Lee Y; Yhim HY; Yang DH; Byun JM; Kang HJ; Kim HJ; Shin HJ; Yoo KH; Suh C;
    Ann Hematol; 2020 Feb; 99(2):223-228. PubMed ID: 31853704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle cell lymphoma: a Turkish Multi-Center Study.
    Okay M; Meletli O; Kelkitli E; Malkan UY; Turgut M; Buyukasik Y; Tekin F; Demiroglu H; Goker H
    J BUON; 2019; 24(5):2084-2089. PubMed ID: 31786879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
    Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Geisler CH; Trneny M; Stilgenbauer S; Kaiser F; Doorduijn JK; Salles G; Szymczyk M; Tilly H; Kanz L; Schmidt C; Feugier P; Thieblemont C; Zijlstra JM; Ribrag V; Klapper W; Pott C; Unterhalt M; Dreyling MH
    J Clin Oncol; 2020 Jan; 38(3):248-256. PubMed ID: 31804876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
    Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
    J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
    Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
    Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
    Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
    Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
    Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
    Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
    Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
    J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Romaguera JE; Wang M; Feng L; Fayad LE; Hagemeister F; McLaughlin P; Rodriguez MA; Fanale M; Orlowski R; Kwak LW; Neelapu S; Oki Y; Pro B; Younes A; Samaniego F; Fowler N; Hartig K; Valentinetti M; Smith J; Ford P; Naig A; Medeiros LJ; Kantarjian HM; Goy A
    Cancer; 2018 Jun; 124(12):2561-2569. PubMed ID: 29723393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study.
    Todorovic M; Balint B; Andjelic B; Stanisavljevic D; Kurtovic NK; Radisavljevic Z; Mihaljevic B
    Med Oncol; 2012 Sep; 29(3):2212-9. PubMed ID: 22170090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.